Embattled OccuLogix falls foul of Nasdaq
This article was originally published in Clinica
Executive Summary
Troubled ophthalmic device company OccuLogix is to see its shares delisted from the Nasdaq Capital Market, with effect from September 18. The Toronto, Ontario-based company had failed to comply with the stock exchange's listing requirements, namely the minimum stockholders' equity and bid price. OccuLogix's shares have been trading consistently below the $1-mark for over a year. The firm said it intends to ask the Nasdaq listing review panel for more time to regain compliance. In the meantime, it will transfer trading of its shares from the Nasdaq to the Over-the-Counter Bulletin Board (OTCBB), on or prior to September 18.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.